preview

Acute Respiratory Distress Syndrome Case Study

Good Essays

Inhaled Epoprostenol in Acute Respiratory Distress Syndrome Razvan Secrian University of Cincinnati Inhaled Epoprostenol in ARDS Acute respiratory distress syndrome (ARDS) is characterized by ventilation and perfusion mismatching that leads to hypoxic respiratory failure. Ashbaugh and colleagues first defined it in 1967 when they described 12 patients with severe acute respiratory failure (Ferguson et al., 2012). “These patients had severe hypoxemia that was refractory to supplemental oxygen, but which in some cases was responsive to the application of positive end-expiratory pressure (PEEP)” (Ferguson et al., 2012, p. 1574). Autopsy also revealed widespread pulmonary inflammation, edema and hyaline membranes (Ferguson et al., 2012). …show more content…

A., Bauer, S. R., Bass, S. N., Sasidhar, M., Mullin, R., & Lam, S. W. (2015). Noninferiority of inhaled epoprostenol to inhaled nitric oxide for the treatment of ARDS. Annals of Pharmacotherapy, 49(10), 1105-1112. doi:10.1177/1060028015595642 Attaway, A. H., Myers, C., Velani, S., & Schilz, R. (2017). Inhaled prostacyclin as salvage therapy for ARDS: Can we find the right patient? Respiratory Care, 62(8), 1113-1115. doi:10.4187/respcare.05708 Ferguson, N. D., Fan, E., Camporota, L., Antonelli, M., Anzueto, A., Beale, R., . . . Ranieri, V. M. (2012). The berlin definition of ARDS: An expanded rationale, justification, and supplementary material. Intensive Care Medicine, 38(10), 1573-1582. doi:10.1007/s00134-012-2682-1 Fuller, B. M., Mohr, N. M., Skrupky, L., Fowler, S., Kollef, M. H., & Carpenter, C. R. (2015). The use of inhaled prostaglandins in patients with ARDS. Chest, 147(6), 1510-1522. doi:10.1378/chest.14-3161 Maca, J., Jor, O., Holub, M., Sklienka, P., Bur A, F., Burda, M., . . . Ev Ik, P. (2016). Past and present ARDS mortality rates: A systematic review. Respiratory Care, 62(1), 113-122. doi:10.4187/respcare.04716 Modrykamien, A. M. (2014). Inhaled epoprostenol in ARDS. Respiratory Care, 59(8), 1312-1313.

Get Access